Skip Navigation


eCAM Advance Access originally published online on October 27, 2007
eCAM 2009 6(3):357-363; doi:10.1093/ecam/nem126
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
6/3/357    most recent
nem126v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Shin, R.
Right arrow Articles by Susa, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shin, R.
Right arrow Articles by Susa, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Improvement of Experimentally Induced Hepatic and Renal Disorders in Rats using Lactic Acid Bacteria-fermented Soybean Extract (BiofermenticsTM)

Ryoichi Shin1, Momoyo Suzuki1, Takeo Mizutani1 and Nobuyuki Susa2

1Central Institute for Health Science, A.L.A. Corporation 40-14 Kitamachi, Seya-ku, Yokohama-city, Kanagawa, 246-0002 and 2Department of Veterinary Public Health, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, 034-8628 Japan

The effects of lactic acid bacteria-fermented soybean extract (BiofermenticsTM; BF) on experimental models of hepatic and renal disorders were investigated in vivo and in vitro. In rat, hepatitis induced by feeding of deoxycholic acid (DCA, 0.5 wt/wt, n = 6) or intraperitoneal injection of D-galactosamine (GMN, 500 mg/body wt, n = 6), the increase in serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) levels were inhibited significantly (P < 0.05) by feeding a diet containing 5% dried BF. Moreover, the BF-administered rat group showed lower concentrations of blood urea nitrogen and a larger amount of urine as compared with values in the control group. Pretreatment of primary cell cultures of rat hepatic and renal cells with BF prior to exposure to dichromate (K2Cr2O7) resulted in a marked decrease of dichromate-induced cytotoxicity as evaluated by the leakage of lactate dehydrogenase The levels of dichromate-induced lipid peroxidation, as monitored by malondialdehyde formation, were also reduced by pretreatment of hepatocytes with BF. These results suggest that BF may play a role in hepatic and renal disorders, and may be useful for maintaining health in humans as well.

Keywords: anti-oxidation – fermentation – hepatitis – lactobacillus – yeasts

For reprints and all correspondence: Ryoichi Shin, Central Institute for Health Science, A.L.A. Corporation 40-14 Kitamachi, Seya-ku, Yokohama-city, Kanagawa, 246-0002 Japan. Tel: +81-45-924-4311; Fax: +81-45-924-4312; E-mail: rshin{at}ciala.co.jp

Received October 12, 2006; accepted June 14, 2007


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.